Report: Surge in Data Integrity Citations Is Tied to Heightened Risk of Inspections

There is a strong correlation between a surge in warning letters over data integrity issues and increased FDA inspections of manufacturers in India and China — one that could cause production headaches for U.S. drugmakers partnering with these facilities.
Source: Drug GMP Report